Andrew Galler

speaker

96 appearances 1 recordings 1 series first heard Feb 2026 last heard 3 Feb

Andrew Galler’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Precision Cardiology With Cytokinetics · 3 Feb 2026 podcast

So you don't have to be calling on every single cardiologist across the country to actually penetrate this population.

Exactly.

And then maybe when I think about some other kind of precision cardio launches in the past couple of years, and maybe when it comes to my mostly is ATTR cardiomyopathy, the prevalence estimates have massively increased as they continue to roll out those drugs.

Do you think we could see the same thing for HCM?

Okay.

And then as I think about your pricing strategy, it seems like your wholesale acquisition cost price is at a slight premium to Bristol's Camzios.

Can you talk about the underlying thinking behind that decision?

So, I mean, HCM still is a relatively fledgling market, so you don't see it becoming more tightly managed over time, such as maybe commercial formularies choosing one drug to promote over another in their formularies.

We haven't seen any evidence of that.

Okay.

And then I know that you're planning an SMDA filing for data from Maple HCM coming up.

How do you see these data really fitting into my Corso's commercial proposition, particularly in light of kind of a meta-analysis recently showing improved efficacy when combining cardiac myosin inhibitors with beta blockers?

So having that head-to-head might not be as meaningful to prescribers.

And then maybe as I just think more broadly about developing the HCM market and as it affects the mycorrhizal launch, what work has Bristol done so far with their Camxios launch that might lay the foundation for a faster ramp for mycorrhizal?

I know we can talk a lot about the second entrant growing the market, but ultimately we'll be competing with CAMSIOs.

So I know there's a lot of kind of minor differences between the two labels and they're almost settled, but broadly what has been initial prescriber feedback on the differences between your REMS and your black box warning between CAMSIOs and myCORSO?

So you've characterized it as minor differences.

You touched on the patient hub a few times.

Maybe you can dig just a little bit on that and what you think is so unique about it and how you work to build that in a bespoke manner rather than, I think you said it earlier, relying on the older architecture of other hubs.

And you did mention as well, drug-drug interactions on the labels for CAMSIOs.

Showing 41–60 of 96 · page 3 of 5